Custom Search

News

Friday 01 August 2003

Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.

By: Clarke LE, Bayerl MG, Ehmann WC, Helm KF.

J Cutan Pathol 2003 Aug;30(7):459-62

BACKGROUND: Antibodies to the B-cell-specific antigen CD20 are widely used for immunohistochemical identification of B-cell lymphomas, approximately 95% of which are strongly CD20-positive. METHODS: We report a 51-year-old male with a CD20-positive systemic B-cell lymphoma who developed a CD20-negative relapse with secondary cutaneous involvement after therapy with the anti-CD20 monoclonal antibody rituximab (Rituxan). RESULTS: Biopsy of a skin nodule demonstrated an atypical lymphocytic infiltrate that was negative for CD20, CD3, lysozyme, and myeloperoxidase, but strongly positive for CD45rb (LCA) and the B-cell marker CD79a. CONCLUSIONS: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase.

Use of this site is subject to the following terms of use